This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ayanian, J. Z. Articles by Braunwald, E. Search for Related Content PubMed PubMed Citation Articles by Ayanian, J. Z. Articles by Braunwald, E. Pubmed/NCBI databases Medline Plus Health Information Heart Attack Related Collections Health policy and outcome research Cardiovascular Pharmacology

(Circulation. 2000;101:2224.)
© 2000 American Heart Association, Inc.

Editorial

Thrombolytic Therapy for Patients With Myocardial Infarction Who Are Older Than 75 Years

Do the Risks Outweigh the Benefits?

John Z. Ayanian, MD, MPP; Eugene Braunwald, MD

From the Division of General Medicine (J.Z.A.) and the Cardiovascular Division (E.B.), Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School; the Department of Health Care Policy, Harvard Medical School (J.Z.A.); and the Partners HealthCare System (E.B.), Boston, Mass.

Correspondence to John Z. Ayanian, MD, MPP, Department of Health Care Policy, Harvard Medical School, 180 Longwood Avenue, Boston, MA 02115. E-mail ayanian@hcp.med.harvard.edu

Key Words: myocardial infarction • thrombolysis • angioplasty • aging • outcome and process assessment (health care)

Thrombolytic therapy represents a major advance in the care of patients with acute myocardial infarction (AMI) that has developed over the past 2 decades. In a meta-analysis of the 9 largest randomized trials conducted between 1982 and 1992 and involving 58 000 patients, this treatment was shown to reduce 35-day mortality, particularly in patients younger than 75 years who had evidence of ST-segment elevation or bundle-branch block and who were treated within 12 hours of the onset of symptoms.¹ Among the 5754 patients in these trials who were 75 years, thrombolytic therapy was associated with an absolute reduction in mortality of 1% (1 life saved for every 100 patients treated), a reduction that did not approach statistical significance. Given the powerful evidence of benefit in younger patients (including those between 65 and 74 years) and the potential benefit in older patients, guidelines for the care of AMI from the American Heart Association and the American College of Cardiology have supported the use of this treatment for patients 75 years who present with ST elevation within 12 hours of symptom onset as a class IIa indication, ie, one for which the "weight of evidence/opinion is in favor of usefulness/efficacy."²

Contrary to this perspective, an observational study by Thiemann et al³ in this issue of Circulation indicates that thrombolytic therapy is not beneficial and could actually be harmful in patients older than 75 years. These investigators assessed the 30-day mortality among patients aged 65 to 86 years in the United States who . . . [Full Text of this Article]

This article has been cited by other articles:

				T. P. Wharton Jr, E. C. Keeley, C. L. Grines, T. P. Wharton Jr, E. C. Keeley, and C. L. Grines The Case for Community Hospital Angioplasty Circulation, November 29, 2005; 112(22): 3509 - 3534. [Full Text] [PDF]

				G Montalescot, H R Andersen, D Antoniucci, A Betriu, M J de Boer, L Grip, F J Neumann, and M T Rothman Recommendations on percutaneous coronary intervention for the reperfusion of acute ST elevation myocardial infarction Heart, June 1, 2004; 90(6): e37 - e37. [Abstract] [Full Text] [PDF]

				M. Cohen, G. F. Gensini, F. Maritz, E. P. Gurfinkel, K. Huber, A. Timerman, M. Krzeminska-Pakula, J. Santopinto, C. Hecquet, L. Vittori, et al. Prospective Evaluation of Clinical Outcomes After Acute ST-Elevation Myocardial Infarction in Patients Who Are Ineligible for Reperfusion Therapy: Preliminary Results From the TETAMI Registry and Randomized Trial Circulation, October 21, 2003; 108(90161): III-14 - 21. [Abstract] [Full Text] [PDF]

				U. Stenestrand and L. Wallentin Fibrinolytic Therapy in Patients 75 Years and Older With ST-Segment-Elevation Myocardial Infarction: One-Year Follow-up of a Large Prospective Cohort Arch Intern Med, April 28, 2003; 163(8): 965 - 971. [Abstract] [Full Text] [PDF]

				S. W. Smith, J. H. Gurwitz, T. J. McLaughlin, D. Ross-Degnan, C. L. Christiansen, and S. B. Soumerai Thrombolytics Are Not Contraindicated in the Very Old Arch Intern Med, October 14, 2002; 162(18): 2139 - 2140. [Full Text] [PDF]

				H. P. Selker, J. R. Beshansky, J. L. Griffith, and for the TPI Trial Investigators* Use of the Electrocardiograph-Based Thrombolytic Predictive Instrument To Assist Thrombolytic and Reperfusion Therapy for Acute Myocardial Infarction: A Multicenter, Randomized, Controlled, Clinical Effectiveness Trial Ann Intern Med, July 16, 2002; 137(2): 87 - 95. [Abstract] [Full Text] [PDF]

				D. R. Thiemann Primary angioplasty for elderly patients with myocardial infarction: Theory, practice and possibilities J. Am. Coll. Cardiol., June 5, 2002; 39(11): 1729 - 1732. [Full Text] [PDF]

				D. R. Thiemann and S. P. Schulman Thrombolytics in elderly patients: A triumph of hope over experience? Can. Med. Assoc. J., May 1, 2001; 164(9): 1301 - 1303. [Full Text] [PDF]